Neoclease Awarded Yearlong Residency at The Engine Following AgingCode Summit

Jun 13, 2025

We’re excited to share that Neoclease has been awarded a one-year residency at The Engine, a venture firm founded by MIT to support breakthrough science and engineering companies. This recognition follows our recent participation in

the Aging Code Summit, where we joined a dynamic community of biotech and longevity innovators.

Our CEO and Co-Founder, Chelsea Trengrove, Ph.D., delivered a compelling pitch on Neoclease’s proprietary AI-driven gene editors, designed to target the genetic root causes of neurodegenerative diseases such as Parkinson’s. Her presentation highlighted how our platform enables gene-specific editing with unprecedented

precision and therapeutic potential.

We’re honored to be selected among such an inspiring cohort of scientists and entrepreneurs. A heartfelt thank you to Daniel Dacey and the Aging Code Summit team for organizing a world-class event and fostering vital conversations around health-

span, biotech innovation, and the future of aging.

We look forward to continuing to build on this momentum, accelerating our research, expanding collaborations, and pushing the boundaries of what’s possible in neurodegenerative disease treatment.

The Engine, a venture firm spun out of MIT, is known for supporting “tough tech” startups transforming foundational science into world-changing companies. Through this residency, Neoclease will gain access to resources, mentorship, and infrastructure to accelerate its research and development efforts.